Ginkgo Bioworks Holdings DNA
NYSE DNA
$6.93 -0.02 (-0.29%)
As of: Sep 4, 2026 · 11:51 AM EDT

Ginkgo Bioworks Holdings (DNA) Non Operating Investment Income (2020 - 2026)

Ginkgo Bioworks Holdings' (DNA) quarterly Non Operating Investment Income came in at -$1.2 million in Q1 2026, up 67.13% YoY from -$726393.7 in Q1 2025, and up 92.49% on a QoQ basis from -$16.2 million in Q4 2025.

Analysis

Ginkgo Bioworks Holdings (DNA) Non Operating Investment Income (2020 - 2026) Analysis & Trends

Ginkgo Bioworks Holdings (DNA) has 7 years of Non Operating Investment Income data on file, last reported at -$1.2 million in Q1 2026.

  • Quarterly Non Operating Investment Income rose 67.13% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$13.9 million (up 53.52% YoY) and the FY2025 annual result came in at -$16.4 million, up 43.07% from the prior year.
  • Non Operating Investment Income climbed to -$1.2 million in Q1 2026, from -$16.2 million in the prior quarter.
  • In the past five years, Non Operating Investment Income ranged from a high of $3.7 million in Q3 2025 to a low of -$38.7 million in Q2 2022.
  • A 5-year average of -$9.1 million and a median of -$6.4 million in 2023 frame the typical range for Non Operating Investment Income.
  • Annual changes were most pronounced in 2023 — Non Operating Investment Income tumbled 1966.21% — and 2025, when it jumped 153.3%.
  • Tracing DNA's Non Operating Investment Income over 5 years: stood at -$13.4 million in 2022, then climbed by 25.03% to -$10.0 million in 2023, then dropped by 25.3% to -$12.5 million in 2024, then retreated by 28.92% to -$16.2 million in 2025, then surged by 92.49% to -$1.2 million in 2026.
  • The last three Non Operating Investment Income figures came in at -$1.2 million (Q1 2026), -$16.2 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Vertex Pharmaceuticals 140.21 Bn 132.36 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 86.04 Bn 78.05 Bn 3.93 Bn -
3 Argenx Se 63.73 Bn 58.55 Bn 1.37 Bn -
4 Moderna 57.59 Bn 52.46 Bn 52.00 Mn -
5 Revolution Medicines 43.98 Bn 43.98 Bn - -
6 BeOne Medicines 40.13 Bn 35.04 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.55 Bn 32.24 Bn 992.69 Mn -
8 Royalty Pharma 28.60 Bn 27.77 Bn - -
9 Insmed 27.70 Bn 26.54 Bn 358.27 Mn -
10 Ginkgo Bioworks Holdings 430.31 Mn 345.78 Mn 18.44 Mn 1.99 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.99 Mn
Mar 31, 2026 -1.21 Mn
Dec 31, 2025 -16.17 Mn
Sep 30, 2025 3.68 Mn
Jun 30, 2025 -229,000.00
Mar 31, 2025 -3.69 Mn
Dec 31, 2024 -12.55 Mn
Sep 30, 2024 -6.91 Mn
Jun 30, 2024 -6.83 Mn
Mar 31, 2024 -2.54 Mn
Dec 31, 2023 -10.01 Mn
Sep 30, 2023 -36.32 Mn
Jun 30, 2023 -2.12 Mn
Mar 31, 2023 -6.37 Mn
Dec 31, 2022 -13.35 Mn
Sep 30, 2022 -1.76 Mn
Jun 30, 2022 -38.67 Mn
Mar 31, 2022 450,000.00
Dec 31, 2021 -14.55 Mn
Sep 30, 2021 -12.37 Mn